Modulation of Aβ42 fibrillogenesis by glycosaminoglycan structure

FASEB Journal

Volumn 24, Issue 11, 2010, Pages 4250-4261

  Valle Delgado, Juan José ^a,b   Alfonso Prieto, Mercedes ^c,e   De Groot, Natalia S ^f   Ventura, Salvador ^f   Samitier, Josep ^a,d   Rovira, Carme ^c,e,g   Fernàndez Busquets, Xavier ^a,b  

^a INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Institut de Quimica Teorica i Computacional IQTCUB   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Computer Simulation and Modeling Laboratory ^*  (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Alzheimer's disease; Amyloid fibril structure; Fibrillogenesis enhancers and inhibitors; Polysaccharides

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; CHITOSAN; GLYCOSAMINOGLYCAN; HYALURONIC ACID; PEPTIDE; POLY(VINYL SULFATE); POLYVINYL DERIVATIVE; PROTEINASE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ARTICLE; ATOMIC FORCE MICROSCOPY; BETA SHEET; BINDING AFFINITY; CIRCULAR DICHROISM; CONTROLLED STUDY; FIBRILLOGENESIS; FLUORESCENCE MICROSCOPY; FLUORESCENCE SPECTROSCOPY; INCUBATION TIME; INFRARED SPECTROSCOPY; MOLECULAR DYNAMICS; NERVE CELL DIFFERENTIATION; NEUROFILAMENT; NEUROMODULATION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN STABILITY; PROTEIN STRUCTURE; SULFATION; AMINO ACID SEQUENCE; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PEPTIDES; GLYCOSAMINOGLYCANS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY;

EID: 78649898216     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-153551     Document Type: Article

References (78)

1. Hardy, J. A., and Higgins, G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185
2. Mudher, A., and Lovestone, S. (2002) Alzheimer's disease - do tauists and baptists finally shake hands? Trends Neurosci. 25, 22-26
3. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I. R., McGeer, P. L., O'Banion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421
4. Mattson, M. P. (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639
5. Hu, J., Akama, K. T., Krafft, G. A., Chromy, B. A., and Van Eldik, L. J. (1998) Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785, 195-206
6. Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., and Glabe, C. G. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17294-17300
7. Mattson, M. P. (2007) Calcium and neurodegeneration. Aging Cell. 6, 337-350
8. Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., Kagan, B., Ghiso, J., and Lal, R. (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U. S. A. 102, 10427-10432
9. Spillantini, M. G., and Goedert, M. (1998) Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21, 428-433
10. Wenk, G. L. (2003) Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry 64, 7-10
11. Sisodia, S. S., and George-Hyslop, P. H. (2002) γ-Secretase, Notch, Aβ and Alzheimer's disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281-290
12. Antzutkin, O. N. (2004) Amyloidosis of Alzheimer's Aβ peptides: solid-state nuclear magnetic resonance, electron paramagnetic resonance, transmission electron microscopy, scanning transmission electron microscopy and atomic force microscopy studies. Magn. Reson. Chem. 42, 231-246
13. Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B., and Teplow, D. B. (2003) Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. U. S. A. 100, 330-335
14. Mastrangelo, I. A., Ahmed, M., Sato, T., Liu, W., Wang, C., Hough, P., and Smith, S. O. (2006) High-resolution atomic force microscopy of soluble Aβ42 oligomers. J. Mol. Biol. 358, 106-119
15. 1-42 fibrillogenesis with atomic force microscopy. FASEB J. 19, 1344-1346
16. Goldsbury, C. S., Wirtz, S., Müller, S. A., Sunderji, S., Wicki, P., Aebi, U., and Frey, P. (2000) Studies on the in vitro assembly of Aβ 1-40: implications for the search for Aβ fibril formation inhibitors. J. Struct. Biol. 130, 217-231
17. Fernàndez-Busquets, X., de Groot, N. S., Fernandez, D., and Ventura, S. (2008) Recent structural and computational insights into conformational diseases. Curr. Med. Chem. 15, 1336-1349
18. Naito, A., and Kawamura, I. (2007) Solid-state NMR as a method to reveal structure and membrane-interaction of amyloidogenic proteins and peptides. Biochim. Biophys. Acta 1768, 1900-1912
19. Lührs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Döbeli, H., Schubert, D., and Riek, R. (2005) 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc. Natl. Acad. Sci. U. S. A. 102, 17342-17347
20. 1-42 peptide into stable fibrils of reduced cytotoxicity. J. Biol. Chem. 283, 32471-32483
21. Hirschfield, G. M., and Hawkins, P. N. (2003) Amyloidosis: new strategies for treatment. Int. J. Biochem. Cell Biol. 35, 1608-1613
22. Selkoe, D. J. (1997) Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275, 630-631
23. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95, 6448-6453
24. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489
25. 1-42 into globular neurotoxins. Biochemistry 42, 12749-12760
26. Ferreira, S. T., Vieira, M. N., and De Felice, F. G. (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59, 332-345
27. Roher, A. E., Baudry, J., Chaney, M. O., Kuo, Y. M., Stine, W. B., and Emmerling, M. R. (2000) Oligomerization and fibril assembly of the amyloid-β protein. Biochim. Biophys. Acta 1502, 31-43
28. Serpell, L. C. (2000) Alzheimer's amyloid fibrils: structure and assembly. Biochim. Biophys. Acta 1502, 16-30
29. Ruoslahti, E. (1996) Brain extracellular matrix. Glycobiology 6, 489-492
30. Ancsin, J. B. (2003) Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 10, 67-79
31. Van Horssen, J., Wesseling, P., van den Heuvel, L. P., de Waal, R. M., and Verbeek, M. M. (2003) Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2, 482-492
32. Snow, A. D., Mar, H., Nochlin, D., Kimata, K., Kato, M., Suzuki, S., Hassell, J., and Wight, T. N. (1988) The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Pathol. 133, 456-463
33. Snow, A. D., Mar, H., Nochlin, D., Kresse, H., and Wight, T. N. (1992) Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. J. Histochem. Cytochem. 40, 105-113
34. Snow, A. D., Nochlin, D., Sekiguchi, R., and Carlson, S. S. (1996) Identification and immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Exp. Neurol. 138, 305-317
35. Su, J. H., Cummings, B. J., and Cotman, C. W. (1992) Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease. Neuroscience 51, 801-813
36. DeWitt, D. A., Silver, J., Canning, D. R., and Perry, G. (1993) Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp. Neurol. 121, 149-152
37. Gupta-Bansal, R., Frederickson, R. C., and Brunden, K. R. (1995) Proteoglycan-mediated inhibition of Aβ proteolysis. A potential cause of senile plaque accumulation. J. Biol. Chem. 270, 18666-18671
38. Castillo, G. M., Cummings, J. A., Yang, W., Judge, M. E., Sheardown, M. J., Rimvall, K., Hansen, J. B., and Snow, A. D. (1998) Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47, 612-620
39. Potter-Perigo, S., Hull, R. L., Tsoi, C., Braun, K. R., Andrikopoulos, S., Teague, J., Bruce, V. C., Kahn, S. E., and Wight, T. N. (2003) Proteoglycans synthesized and secreted by pancreatic islet β-cells bind amylin. Arch. Biochem. Biophys. 413, 182-190
40. Ancsin, J. B., and Kisilevsky, R. (1999) The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274, 7172-7181
41. Cohlberg, J. A., Li, J., Uversky, V. N., and Fink, A. L. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 41, 1502-1511
42. Supattapone, S. (2004) Prion protein conversion in vitro. J. Mol. Med. 82, 348-356
43. 2-microglobulin under physiological conditions. Kidney Int. 72, 174-181
44. Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., and Crowther, R. A. (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550-553
45. McLaurin, J., Franklin, T., Zhang, X., Deng, J., and Fraser, P. E. (1999) Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans. Effects on fibril nucleation and growth. Eur. J. Biochem. 266, 1101-1110
46. Castillo, G. M., Lukito, W., Wight, T. N., and Snow, A. D. (1999) The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. J. Neurochem. 72, 1681-1687
47. Woods, A. G., Cribbs, D. H., Whittemore, E. R., and Cotman, C. W. (1995) Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate β-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain. Res. 697, 53-62
48. Fernàndez-Busquets, X., Ponce, J., Bravo, R., Arimon, M., Martiáñez, T., Gella, A., Cladera, J., and Durany, N. (2010) Modulation of amyloid β peptide1-42 cytotoxicity and aggregation in vitro by glucose and chondroitin sulfate. Curr. Alzheimer Res. 7, 428-438
49. Pollack, S. J., Sadler, I. I., Hawtin, S. R., Tailor, V. J., and Shearman, M. S. (1995) Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β-amyloid in rat PC12 cells. Neurosci. Lett. 184, 113-116
50. 1-40) are modulated by sulfate moieties of heparin. Neurosci. Res. 66, 380-389
51. Brückner, G., Hausen, D., Härtig, W., Drlicek, M., Arendt, T., and Brauer, K. (1999) Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected by cytoskeletal changes in Alzheimer's disease. Neuroscience 92, 791-805
52. Díaz-Nido, J., Wandosell, F., and Avila, J. (2002) Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 23, 1323-1332
53. McLaurin, J., and Fraser, P. E. (2000) Effect of amino-acid substitutions on Alzheimer's amyloid-β peptide-glycosaminoglycan interactions. Eur. J. Biochem. 267, 6353-6361
54. Alexandrescu, A. T. (2005) Amyloid accomplices and enforcers. Protein. Sci. 14, 1-12
55. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. (1992) Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325-327
56. Pearlman, D. A., Case, D. A., Caldwell, J. W., Ross, W. S., Cheatham, T. E., Debolt, S., Ferguson, D., Seibel, G., and Kollman, P. (1995) AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 91, 1-41
57. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38
58. Surewicz, W. K., Mantsch, H. H., and Chapman, D. (1993) Determination of protein secondary structure by Fourier transform infrared spectroscopy: a critical assessment. Biochemistry 32, 389-394
59. LeVine, H., III (1993) Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410
60. Fraser, P. E., Darabie, A. A., and McLaurin, J. A. (2001) Amyloid-β interactions with chondroitin sulfate-derived monosaccharides and disaccharides. Implications for drug development. J. Biol. Chem. 276, 6412-6419
61. Haxaire, K., Braccini, I., Milas, M., Rinaudo, M., and Pérez, S. (2000) Conformational behavior of hyaluronan in relation to its physical properties as probed by molecular modeling. Glycobiology 10, 587-594
62. Almond, A., and Sheehan, J. K. (2000) Glycosaminoglycan conformation: do aqueous molecular dynamics simulations agree with x-ray fiber diffraction? Glycobiology 10, 329-338
63. Rodríguez-Carvajal, M. A., Imberty, A., and Pérez, S. (2003) Conformational behavior of chondroitin and chondroitin sulfate in relation to their physical properties as inferred by molecular modeling. Biopolymers 69, 15-28
64. Mulloy, B., Forster, M. J., Jones, C., and Davies, D. B. (1993) N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem. J. 293, 849-858
65. Silva, J. L., Lima, L. M., Foguel, D., and Cordeiro, Y. (2008) Intriguing nucleic-acid-binding features of mammalian prion protein. Trends Biochem. Sci. 33, 132-140
66. Calamai, M., Kumita, J. R., Mifsud, J., Parrini, C., Ramazzotti, M., Ramponi, G., Taddei, N., Chiti, F., and Dobson, C. M. (2006) Nature and significance of the interactions between amyloid fibrils and biological polyelectrolytes. Biochemistry 45, 12806-12815
67. Kirschner, D. A., Abraham, C., and Selkoe, D. J. (1986) X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-β conformation. Proc. Natl. Acad. Sci. U. S. A. 83, 503-507
68. Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., and Blake, C. C. (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729-739
69. Yui, T., Imada, K., Okuyama, K., Obata, Y., Suzuki, K., and Ogawa, K. (1994) Molecular and crystal structure of the anhydrous form of chitosan. Macromolecules 27, 7601-7605
70. DeGroot, J. (2004) The AGE of the matrix: chemistry, consequence and cure. Curr. Opin. Pharmacol. 4, 301-305
71. Valente, T., Gella, A., Fernàndez-Busquets, X., Unzeta, M., and Durany, N. (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol. Dis. 37, 67-76
72. Cooke, B. M., Lingelbach, K., Bannister, L. H., and Tilley, L. (2004) Protein trafficking in Plasmodium falciparum-infected red blood cells. Trends Parasitol. 20, 581-589
73. Adda, C. G., Murphy, V. J., Sunde, M., Waddington, L. J., Schloegel, J., Talbo, G. H., Vingas, K., Kienzle, V., Masciantonio, R., Howlett, G. J., Hodder, A. N., Foley, M., and Anders, R. F. (2009) Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils. Mol. Biochem. Parasitol. 166, 159-171
74. Low, A., Chandrashekaran, I. R., Adda, C. G., Yao, S., Sabo, J. K., Zhang, X., Soetopo, A., Anders, R. F., and Norton, R. S. (2007) Merozoite surface protein 2 of Plasmodium falciparum: expression, structure, dynamics, and fibril formation of the conserved N-terminal domain. Biopolymers 87, 12-22
75. Yang, X., Adda, C. G., Keizer, D. W., Murphy, V. J., Rizkalla, M. M., Perugini, M. A., Jackson, D. C., Anders, R. F., and Norton, R. S. (2007) A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils. J. Pept. Sci. 13, 839-848
76. Barragan, A., Fernandez, V., Chen, Q., von Euler, A., Wahlgren, M., and Spillmann, D. (2000) The Duffy-binding-like domain 1 of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a heparan sulfate ligand that requires 12 mers for binding. Blood 95, 3594-3599
77. Andrews, K. T., Klatt, N., Adams, Y., Mischnick, P., and Schwartz- Albiez, R. (2005) Inhibition of chondroitin-4-sulfate-specific adhesion of Plasmodium falciparum-infected erythrocytes by sulfated polysaccharides. Infect. Immun. 73, 4288-4294
78. Singh, K., Gittis, A. G., Nguyen, P., Gowda, D. C., Miller, L. H., and Garboczi, D. N. (2008) Structure of the DBL3x domain of pregnancy-associated malaria protein VAR2CSA complexed with chondroitin sulfate A. Nat. Struct. Mol. Biol. 15, 932-938